Pathogen News and Research

RSS

Researchers identify inflammatory mechanism related to bone damage in rheumatoid arthritis

In a study aimed at investigating the mechanism responsible for exacerbating rheumatoid arthritis in smokers, researchers at the Center for Research on Inflammatory Diseases, linked to the University of São Paulo in Brazil, discovered a novel path in the inflammatory process associated with the bone damage caused by rheumatoid arthritis.

18 Mar 2021

Could cinnamon modulate the immune response in severe COVID-19?

A new study describes the potential for two common plant products to make a difference in the management of severe COVID-19.

18 Mar 2021

Social distancing can be highly effective at preventing outbreaks, says public health expert

Eric Shattuck, assistant professor of research in the UTSA Institute for Health Disparities Research (IHDR) at The University of Texas at San Antonio, is studying the phenomenon of social distancing in response to infectious disease and its effects on pathogen transmission and the health of individuals and communities.

18 Mar 2021

Compromised immunity can allow SARS-CoV-2 to evade the immune system

The vast majority of people infected with SARS-CoV-2 clear the virus, but those with compromised immunity--such as individuals receiving immune-suppressive drugs for autoimmune diseases--can become chronically infected.

17 Mar 2021

Researchers uncover potential new target for anti-COVID-19 therapies

Researchers from Cleveland Clinic's Florida Research and Innovation Center have identified a potential new target for anti-COVID-19 therapies.

16 Mar 2021

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

An interesting new study deals with the effects of the natural mutations in the spike antigen of the SARS-CoV-2, the pathogen that is responsible for the ongoing coronavirus disease pandemic.

16 Mar 2021

The role of RNA capping of SARS-CoV-2 in immunity evasion

The SARS-CoV-2 pathogen successfully uses multiple immune evasion mechanisms to achieve infection within its host. An intriguing new study describes one such process, which may help develop drugs to counteract the virus more effectively.

16 Mar 2021

New study tests how mutations in SARS-CoV-2 affect antibody neutralization

Using pseudoviruses with single amino acid substitutions, researchers found that mutations in SARS-CoV-2 reduce monoclonal antibody neutralization differently. However, convalescent sera samples did not lose neutralization potency many and were also effective against the B.1.1.7 (UK-derived) strain.

16 Mar 2021

Engineered mouse Intestine Chip platform can help study host-microbiome interactions

Trillions of commensal microbes live on the mucosal and epidermal surfaces of the body and it is firmly established that this microbiome affects its host's tolerance and sensitivity of the host to a variety of pathogens.

16 Mar 2021

Blight leads to increase in disease-carrying mosquitoes

Louisiana State University researchers recently published findings that blight leads to an increased abundance of disease-carrying mosquitoes.

15 Mar 2021

The role of nanotechnology in the fight against COVID-19

Appearing in the journal Nanomedicine, the review summarized all the exciting advances made using diverse nanomaterials (polymeric, inorganic self-assembling materials and peptide-based) towards COVID-19 prevention, diagnosis and therapy.

15 Mar 2021

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

A surprising new preprint, released on the medRxiv* server, suggests that the beneficial effects of convalescent plasma (CP) in this disease stem not only from the presence of neutralizing antibodies, but also the immunomodulatory effects of this plasma that shapes the host immune response.

15 Mar 2021

Study maps crucial component of long-term immune response to SARS-CoV-2

Researchers in the United States have found that protective antibodies generated against the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)– the agent that causes coronavirus disease 2019 (COVID-19) – also protect against viral variants.

14 Mar 2021

SARS-CoV-2 did not change much when it jumped from bats to human hosts

How much did SARS-CoV-2 need to change in order to adapt to its new human host? In a research article published in the open access journal PLOS Biology Oscar MacLean, Spyros Lytras at the University of Glasgow, and colleagues, show that since December 2019 and for the first 11 months of the SARS-CoV-2 pandemic there has been very little 'important' genetic change observed in the hundreds of thousands of sequenced virus genomes.

13 Mar 2021

Study identifies three novel binding receptors for SARS-CoV-2

A team of scientists from the United Kingdom recently conducted a large-scale screening of several membrane-bound and soluble host cell receptors to identify novel binding partners for SARS-CoV-2. They have identified three novel receptors expressed on the human cell membrane; of which, one binds to SARS-CoV-2 spike with similar affinity as angiotensin-converting enzyme 2 (ACE2).

12 Mar 2021

SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment, study finds

Researchers have found that SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment. Therefore, strategies such as focusing on limiting the production of IFN, rather than its function, could restrict the mechanism of SARS-CoV-2 that increases its viral load with delayed or absent symptoms.

12 Mar 2021

Texas Biomed receives DoD subcontracts to assess SARS-CoV-2 decontamination technologies

Texas Biomedical Research Institute received two Department of Defense's (DoD) Defense Health Agency subcontracts to assess the efficacy of surface coating and aerosolized decontamination technologies to combat SARS-CoV-2 and other respiratory pathogens on surfaces and in the air.

11 Mar 2021